ReviewExpert opinion on investigational drugs2009
Clinical development of novel proteasome inhibitors for cancer treatment.
Review in Expert opinion on investigational drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05218603 (A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for Autologous Stem Cell Transplantation (ASCT): Alcyone-optimized Real World Evidence (RWE) Data
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis.Bioscience reports · 2017Pooled it
- Gene expression profiling predicts the development of oral cancer.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- Pulmonary light chain deposition disease secondary to Sjögren disease: a case report.Frontiers in immunology · 2026Article
- From locus to gene: causal inference and experimental validation prioritize PSMA4 as a candidate target in lung adenocarcinoma.American journal of cancer research · 2026Article
- A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis.Journal of experimental & clinical cancer research : CR · 2025Review
- Proteasome inhibitor MG132 modulates signal transduction pathways in ELT3 uterine leiomyoma cells.Experimental and therapeutic medicine · 2025Article
- The role of GZMA as a target of cysteine and biomarker in Alzheimer's disease, pelvic organ prolapse, and tumor progression.Frontiers in pharmacology · 2024Article
- Neuroprotective mechanisms of red clover and soy isoflavones in Parkinson's disease models.Food & function · 2021Article
- Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.Medical oncology (Northwood, London, England) · 2021Article
- miR-33b-3p Acts as a Tumor Suppressor by TargetingFrontiers in oncology · 2021Article
- Proteasome Inhibitor MG132 is Toxic and Inhibits the Proliferation of Rat Neural Stem Cells but Increases BDNF Expression to Protect Neurons.Biomolecules · 2020Article
- Article
- Soybean lecithin stabilizes disulfiram nanosuspensions with a high drug-loading content: remarkably improved antitumor efficacy.Journal of nanobiotechnology · 2020Article
- The Impact of theBioMed research international · 2020Article
- E6AP Promotes a Metastatic Phenotype in Prostate Cancer.iScience · 2019Article
- Genistein inhibits human papillary thyroid cancer cell detachment, invasion and metastasis.Journal of Cancer · 2019Article
- Review
- A Comparative Cytotoxic Evaluation of Disulfiram Encapsulated PLGA Nanoparticles on MCF-7 Cells.International journal of hematology-oncology and stem cell research · 2017Article
- The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction.Oncotarget · 2016Article
- Multicolor monitoring of the proteasome's catalytic signature.ACS chemical biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEmerging evidence demonstrates that targeting the tumor proteasome is a promising strategy for cancer therapy.
objectiveThis review summarizes recent results from cancer clinical trials using specific proteasome inhibitors or some natural compounds that have proteasome-inhibitory effects.
methodsA literature search was carried out using PubMed. Results about the clinical application of specific proteasome inhibitors and natural products with proteasome-inhibitory activity for cancer prevention or therapy were reviewed. RESULTS/
conclusionBortezomib, the reversible proteasome inhibitor that first entered clinical trials, has been studied extensively as a single agent and in combination with glucocorticoids, cytotoxic agents, immunomodulatory drugs and radiation as treatment for multiple myeloma and other hematological malignancies. The results in some cases have been impressive. There is less evidence of bortezomib's efficacy in solid tumors. Novel irreversible proteasome inhibitors, NPI-0052 and carfilzomib, have also been developed and clinical trials are underway. Natural products with proteasome-inhibitory effects, such as green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG), soy isoflavone genistein, and the spice turmeric compound curcumin, have been studied alone and in combination with traditional chemotherapy and radiotherapy against various cancers. There is also interest in developing these natural compounds as potential chemopreventive agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.